GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (4)
  • 2020-2024  (4)
  • 1
    In: Blood Cancer Discovery, American Association for Cancer Research (AACR), Vol. 3, No. 3 ( 2022-05-05), p. 181-193
    Abstract: Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non–B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non–recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. Significance: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171
    Type of Medium: Online Resource
    ISSN: 2643-3230 , 2643-3249
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 29, No. 12_Supplement ( 2020-12-01), p. PO-076-PO-076
    Abstract: Introduction: Large segments of the United States population do not receive quality cancer care due to pervasive and systemic inequities. Disparate cancer care is associated with increased morbidity and mortality. Multi-component, multi-level interventions can address inequities and improve care, but only if they reach populations of interest. Intervention studies often under-enroll populations of interest, despite having an adequate eligible pool. Procedures: The Alliance to Advance Patient-Centered Cancer Care supports six grantees across the US to implement diverse multi-component (e.g., access, symptom monitoring, wellness, survivorship), multi-level (e.g., patients, clinicians, caregivers) intervention programs with the shared goals of reducing disparities, increasing patient engagement, and improving the quality of cancer care. The Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework informs the evaluation efforts across the six sites. An important first step is to reach and enroll individuals who are most in need of cancer screening or access to cancer treatment. Target populations across sites include underrepresented minorities (e.g., Black and Latinx persons), those who speak English as a second language, and rural residents. Each participating site defined the target population(s) for their program. The sites used four key strategies to reach their target populations, which included: lay and clinical navigators, community advisory boards, data algorithms to conduct eligibility screening from the electronic health record, and dynamic community-based participatory research approaches. For years 2018-2019, we evaluated the demographic characteristics of participants recruited to program interventions compared to the overall demographic characteristics of each site’s pool of potentially eligible participants. Summary data: Of 4,692 potentially eligible participants, the six sites have enrolled 1,880 participants to date. Below we report the proportion of individuals with selected characteristics from the total enrolled: Black adults: 39% enrolled, (n=733), Latinx adults: 23% enrolled, (n=432), English as second language speakers: 19% enrolled, (n=357), and rural residents: 25% enrolled, (n=470). These proportions were similar or exceeded the proportions observed across the entire pool of eligible persons. Specifically, of 4,692 eligible persons across all sites, 35% were Black adults, 19% were Latinx adults, 15% spoke English as a second language, and 23% resided in rural areas. Conclusion: The Alliance to Advance Patient-Centered Cancer Care grantees have met or exceeded target enrollments from underserved groups to patient-centered intervention programs. Intentional strategies that include human resources, technology, and community engagement are needed and can be successful in improving access to high-quality cancer screening, treatment, and supportive care. Citation Format: Debra L. Barton, Bidisha Ghosh, Heidi A. Hamann, Sanja Percac-Lima, Adrian S. Dobs, Michelle J. Naughton, Roland P. Matthews, Sheryl Gabram-Mendola, Melissa A. Simon, Yvonne Bueno, Beverly Moy, Electra D. Paskett, Sankirtana M. Danner, Bingxin Chen, Robert J. Ploutz- Snyder, Christopher R. Friese. Strategies to improve the reach of interventions to address inequities in cancer care: Results from a six-site initiative [abstract]. In: Proceedings of the AACR Virtual Conference: Thirteenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2020 Oct 2-4. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(12 Suppl):Abstract nr PO-076.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Discovery, American Association for Cancer Research (AACR), Vol. 10, No. 10 ( 2020-10-01), p. 1514-1527
    Abstract: Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. Significance: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access. This article is highlighted in the In This Issue feature, p. 1426
    Type of Medium: Online Resource
    ISSN: 2159-8274 , 2159-8290
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2607892-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2023
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 32, No. 6 ( 2023-06-01), p. 748-759
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 32, No. 6 ( 2023-06-01), p. 748-759
    Abstract: Studies have shown an increased risk of severe SARS-CoV-2–related (COVID-19) disease outcome and mortality for patients with cancer, but it is not well understood whether associations vary by cancer site, cancer treatment, and vaccination status. Methods: Using electronic health record data from an academic medical center, we identified a retrospective cohort of 260,757 individuals tested for or diagnosed with COVID-19 from March 10, 2020, to August 1, 2022. Of these, 52,019 tested positive for COVID-19 of whom 13,752 had a cancer diagnosis. We conducted Firth-corrected logistic regression to assess the association between cancer status, site, treatment, vaccination, and four COVID-19 outcomes: hospitalization, intensive care unit admission, mortality, and a composite “severe COVID” outcome. Results: Cancer diagnosis was significantly associated with higher rates of severe COVID, hospitalization, and mortality. These associations were driven by patients whose most recent initial cancer diagnosis was within the past 3 years. Chemotherapy receipt, colorectal cancer, hematologic malignancies, kidney cancer, and lung cancer were significantly associated with higher rates of worse COVID-19 outcomes. Vaccinations were significantly associated with lower rates of worse COVID-19 outcomes regardless of cancer status. Conclusions: Patients with colorectal cancer, hematologic malignancies, kidney cancer, or lung cancer or who receive chemotherapy for treatment should be cautious because of their increased risk of worse COVID-19 outcomes, even after vaccination. Impact: Additional COVID-19 precautions are warranted for people with certain cancer types and treatments. Significant benefit from vaccination is noted for both cancer and cancer-free patients.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...